JP2024514163A5 - - Google Patents

Info

Publication number
JP2024514163A5
JP2024514163A5 JP2023562872A JP2023562872A JP2024514163A5 JP 2024514163 A5 JP2024514163 A5 JP 2024514163A5 JP 2023562872 A JP2023562872 A JP 2023562872A JP 2023562872 A JP2023562872 A JP 2023562872A JP 2024514163 A5 JP2024514163 A5 JP 2024514163A5
Authority
JP
Japan
Application number
JP2023562872A
Other languages
Japanese (ja)
Other versions
JPWO2022221726A5 (https=
JP2024514163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025115 external-priority patent/WO2022221726A2/en
Publication of JP2024514163A publication Critical patent/JP2024514163A/ja
Publication of JP2024514163A5 publication Critical patent/JP2024514163A5/ja
Publication of JPWO2022221726A5 publication Critical patent/JPWO2022221726A5/ja
Pending legal-status Critical Current

Links

JP2023562872A 2021-04-16 2022-04-15 Bcma指向性t細胞療法を用いた併用療法 Pending JP2024514163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176196P 2021-04-16 2021-04-16
US63/176,196 2021-04-16
PCT/US2022/025115 WO2022221726A2 (en) 2021-04-16 2022-04-15 Combination therapies with bcma-directed t cell therapy

Publications (3)

Publication Number Publication Date
JP2024514163A JP2024514163A (ja) 2024-03-28
JP2024514163A5 true JP2024514163A5 (https=) 2025-04-18
JPWO2022221726A5 JPWO2022221726A5 (https=) 2025-04-18

Family

ID=81846411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562872A Pending JP2024514163A (ja) 2021-04-16 2022-04-15 Bcma指向性t細胞療法を用いた併用療法

Country Status (9)

Country Link
US (1) US20240207310A1 (https=)
EP (1) EP4322959A2 (https=)
JP (1) JP2024514163A (https=)
KR (1) KR20230171468A (https=)
CN (1) CN118201618A (https=)
AU (1) AU2022258832A1 (https=)
CA (1) CA3214683A1 (https=)
IL (1) IL307612A (https=)
WO (1) WO2022221726A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015158671A1 (en) 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
RU2685500C2 (ru) 2014-09-22 2019-04-18 Сакми Кооператива Мекканичи Имола Сочиета' Кооператива Линия для производства индивидуальных изделий последовательно в непрерывном цикле
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
CN106014789A (zh) 2016-06-25 2016-10-12 郭远军 一种悬吊式一体化反装斜击式水轮发电机及其做功方法
BR112020010579A2 (pt) * 2017-11-30 2020-11-10 Novartis Ag receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
CA3105813A1 (en) * 2018-07-11 2020-01-16 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
WO2020097403A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN116157125A (zh) * 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合

Similar Documents

Publication Publication Date Title
JP2024511373A5 (https=)
JP2024514163A5 (https=)
BR102023007252A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BY13135U (https=)
CN307046076S (https=)
BY13149U (https=)
BY13145U (https=)
BY13144U (https=)
BY13143U (https=)
BY13151U (https=)
CN307049297S (https=)
CN307048316S (https=)
CN307047880S (https=)
CN307047685S (https=)
CN307047469S (https=)
BY13142U (https=)
CN307044779S (https=)
CN307046377S (https=)
CN307044906S (https=)
BY13141U (https=)
CN307045991S (https=)
BY13157U (https=)
CN307044505S (https=)